| Literature DB >> 6135395 |
Y Uchida, M Nakamura, S Shimizu, Y Shirasawa, M Fujii.
Abstract
Single oral administration of K-351 showed a long lasting antihypertensive action in spontaneously hypertensive rats, accompanied by slight bradycardia. K-351 reduced systolic and diastolic blood pressures almost to the same degree. K-351 showed a competitive antagonistic effect on norepinephrine-induced contraction of isolated canine blood vessels. This alpha-adrenoceptor blocking action of K-351 was about 5 times less potent than that of phentolamine. Furthermore, K-351 produced a nitroglycerin-like relaxant action on isolated blood vessels previously contracted with high K+. K-351 showed a nonselective beta-adrenoceptor blocking action in isolated guinea-pig atrium and trachea, and its action was about 2 times more potent than that of propranolol. K-351 did not show an intrinsic sympathomimetic action. In anesthethized dogs, low doses of K-351 reduced the heart rate and antagonized the positive chronotropic and hypotensive responses to isoproterenol. In higher doses, K-351 lowered the blood pressure and showed an antagonistic action on the pressor response to phenylephrine. The desnitro compound of K-351 was deprived of vasoactive properties on isolated blood vessels and hypotensive activity. Results have revealed that K-351 has both beta-adrenoceptor blocking and vasoactive properties which may result in an antihypertensive effect without reflex tachycardia in hypertensive animals.Entities:
Mesh:
Substances:
Year: 1983 PMID: 6135395
Source DB: PubMed Journal: Arch Int Pharmacodyn Ther ISSN: 0003-9780